December 10, 2012 / 1:58 PM / 5 years ago

BRIEF-Celldex Therapeutics up in premarket after CDX-011 phase 2 study results

NEW YORK, Dec 10 (Reuters) - Celldex Therapeutics Inc : * Up 9.6 percent to $6.05 in premarket after CDX-011 phase 2 study results in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below